Kane Biotech Inc V.KNE

Alternate Symbol(s): KNBIF

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.

TSXV:KNE - Post by User

Kane Biotech Inc > Apart from traveling

<< Previous

Bullboard Posts

Next >>

Comment by RoyMax123on Jun 13, 2024 12:43pm

51 Views

Post# 36087390

RE:RE:Apart from traveling

Hopefully that "before end of June" deadline will be more accurate than all others deadline they gave in the past.

francoisl13 wrote: The next big news will be the start of the 'Revyve' commercial production (before end of June, per KNE) and product shipment to Progenacare. This should prevent them to run out of cash for a little while...
It was said that the ACNE trial and the Dispersin B phase 1 study could start a little later than what was expected but, things are moving forward, just at a slower pace.
The above is my understanding of what the company announced in their last quaterly meeting.
GLTA

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages